The 61st Annual Meeting of the European Association for the Study of Diabetes (EASD 2025) took place in Vienna, Austria, on October 15, 2025, showcasing significant advancements in diabetes management. Sinocare highlighted its expertise in this field through an international industry symposium and an exclusive networking dinner, aimed at enhancing collaboration among professionals.
A key highlight of the symposium was the presentation of the iCan CGM system, which received commendations for its clinical performance. Esteemed experts, including Professor Lori Laffel, Dr. Guido Freckmann, and Professor Julia Mader, shared their collaborative research findings related to the iCan CGM. The discussions revolved around the themes of “Performance, Practicality, and Pediatrics,” presenting promising data from recent studies conducted in Germany and the United States involving both adult and pediatric populations.
The session emphasized the practical application of Continuous Glucose Monitoring (CGM) systems in real-world scenarios, featuring insights from a leading pediatric diabetes center. The dialogue also touched on how diabetes technology can influence travel and employment opportunities for those living with diabetes, particularly for individuals passionate about aviation.
Launch of the Next-Generation iCan i6 CGM
Sinocare unveiled its next-generation iCan i6 CGM system, which became the focal point at the company’s booth. This system boasts a 15-day accuracy and comfortable wear, enhancing user experience with several upgrades. These include a one-step application process with a smaller, lighter sensor, support for 27 languages to ensure global accessibility, and a built-in altitude compensation algorithm for reliable readings at high elevations. Furthermore, enhanced mobile app integration allows for an “effortless monitoring” experience accessible worldwide.
In addition, Sinocare’s partner, A.Menarini Diagnostics s.r.l, showcased the co-branded GlucoMen® iCan CGM system. Menarini emphasized the system’s latest features and clinical benefits through an engaging booth experience, which attracted considerable interest from medical professionals attending the event.
Introducing the “A+C” Diabetes Ecosystem
On September 15, as part of its ongoing initiatives, Sinocare hosted a private dinner seminar to introduce the new “A+C” Diabetes Prevention and Control Ecosystem to key partners. This innovative model integrates AGEscan non-invasive screening with CGM technology to facilitate early risk detection and precision intervention.
Sinocare also presented its hospital glucose management solution, designed to connect outpatient and inpatient care seamlessly. This approach aims to improve efficiency and quality of care through comprehensive digital diabetes management.
Sinocare’s presence at EASD 2025 not only showcased cutting-edge CGM clinical research but also underscored the company’s commitment to integrated prevention and hospital management solutions. By fostering collaborations with global experts and partners, Sinocare reinforced its dedication to addressing patient and clinical needs through technological innovation.
With these advancements, Sinocare aims to set new standards in diabetes management, enhancing the quality of life for individuals living with this chronic condition.
